CN113226314B - 吡咯烷化合物的晶体 - Google Patents

吡咯烷化合物的晶体 Download PDF

Info

Publication number
CN113226314B
CN113226314B CN201980086473.9A CN201980086473A CN113226314B CN 113226314 B CN113226314 B CN 113226314B CN 201980086473 A CN201980086473 A CN 201980086473A CN 113226314 B CN113226314 B CN 113226314B
Authority
CN
China
Prior art keywords
crystals
crystal
pyrrolidine
phosphoric acid
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980086473.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN113226314A (zh
Inventor
上田直子
长田裕臣
吉田琢纮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Priority to CN202510224370.1A priority Critical patent/CN120081826A/zh
Priority to CN202510225181.6A priority patent/CN120081827A/zh
Publication of CN113226314A publication Critical patent/CN113226314A/zh
Application granted granted Critical
Publication of CN113226314B publication Critical patent/CN113226314B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980086473.9A 2018-12-28 2019-12-27 吡咯烷化合物的晶体 Active CN113226314B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202510224370.1A CN120081826A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体
CN202510225181.6A CN120081827A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018247437 2018-12-28
JP2018-247437 2018-12-28
PCT/JP2019/051570 WO2020138481A1 (ja) 2018-12-28 2019-12-27 ピロリジン化合物の結晶

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202510224370.1A Division CN120081826A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体
CN202510225181.6A Division CN120081827A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体

Publications (2)

Publication Number Publication Date
CN113226314A CN113226314A (zh) 2021-08-06
CN113226314B true CN113226314B (zh) 2025-03-18

Family

ID=71127176

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201980086473.9A Active CN113226314B (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体
CN202510225181.6A Pending CN120081827A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体
CN202510224370.1A Pending CN120081826A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202510225181.6A Pending CN120081827A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体
CN202510224370.1A Pending CN120081826A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体

Country Status (8)

Country Link
US (2) US12077524B2 (https=)
EP (3) EP4603143A3 (https=)
JP (3) JP6977185B2 (https=)
CN (3) CN113226314B (https=)
ES (1) ES2991904T3 (https=)
MA (1) MA54619A (https=)
TW (2) TWI870228B (https=)
WO (1) WO2020138481A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230016008A (ko) 2020-06-10 2023-01-31 미쓰비시 타나베 파마 코퍼레이션 광선성 피부질환의 예방 또는 치료제
CA3186880A1 (en) 2020-06-10 2021-12-16 Mitsubishi Tanabe Pharma Corporation Prophylactic or therapeutic agent for porphyria
WO2021251450A1 (ja) 2020-06-10 2021-12-16 田辺三菱製薬株式会社 ポルフィリン症の予防又は治療剤
MX2023013044A (es) * 2021-05-06 2023-11-15 Lg Chemical Ltd Forma cristalina v del compuesto agonista del receptor de melanocortina y metodo para preparar la misma.
BR112023022863A2 (pt) * 2021-05-06 2024-01-23 Lg Chemical Ltd Forma cristalina vii do composto agonista do receptor de melanocortina e método para preparar o mesmo
US20240239769A1 (en) * 2021-05-07 2024-07-18 Lg Chem, Ltd. Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same
EP4317148A4 (en) * 2021-05-07 2024-09-18 Lg Chem, Ltd. MELANOCORTIN RECEPTOR AGONIST COMPOUND SULFATE CRYSTALS AND PROCESS FOR PRODUCTION THEREOF
AU2022271120A1 (en) * 2021-05-07 2023-11-09 Lg Chem, Ltd. Crystal form iv of organic acid salts of melanocortin receptor agonist compound, and preparation method thereof
AU2023213357A1 (en) 2022-01-31 2024-08-15 Mitsubishi Tanabe Pharma Corporation Novel use of melanocortin-1 receptor agonist
CN119654150A (zh) 2022-08-03 2025-03-18 田边三菱制药株式会社 含有1-｛2-[（3s,4r）-1-｛[（3r,4r）-1-环戊基-3-氟-4-（4-甲氧基苯基）吡咯烷-3-基]羰基｝-4-（甲氧基甲基）吡咯烷-3-基]-5-（三氟甲基）苯基｝哌啶-4-甲酸或其药学上可接受的盐或者共晶的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458887A (zh) * 2014-05-29 2017-02-22 田边三菱制药株式会社 新型吡咯烷化合物及作为黑皮质素受体激动剂的用途
JP2017105765A (ja) * 2015-11-27 2017-06-15 田辺三菱製薬株式会社 医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143404B2 (en) 2004-09-13 2012-03-27 Ono Pharmaceutical Co., Ltd Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient
CN101365476A (zh) * 2005-10-07 2009-02-11 瓦拉塔药品公司 Dpp-iv抑制剂和胃泌素化合物的联合使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458887A (zh) * 2014-05-29 2017-02-22 田边三菱制药株式会社 新型吡咯烷化合物及作为黑皮质素受体激动剂的用途
JP2017105765A (ja) * 2015-11-27 2017-06-15 田辺三菱製薬株式会社 医薬組成物

Also Published As

Publication number Publication date
EP4603143A2 (en) 2025-08-20
US20250002474A1 (en) 2025-01-02
CN120081826A (zh) 2025-06-03
CN120081827A (zh) 2025-06-03
ES2991904T3 (es) 2024-12-05
JP2025085744A (ja) 2025-06-05
EP3903785A4 (en) 2022-08-10
EP3903785B1 (en) 2024-10-02
CN113226314A (zh) 2021-08-06
TW202039464A (zh) 2020-11-01
EP4434582A2 (en) 2024-09-25
JP6977185B2 (ja) 2021-12-08
TWI870228B (zh) 2025-01-11
TWI834791B (zh) 2024-03-11
US12077524B2 (en) 2024-09-03
EP4603143A3 (en) 2025-11-05
US20220073497A1 (en) 2022-03-10
TW202421621A (zh) 2024-06-01
JP2022024034A (ja) 2022-02-08
EP4434582A3 (en) 2024-12-18
EP3903785A1 (en) 2021-11-03
TW202517631A (zh) 2025-05-01
JP7652682B2 (ja) 2025-03-27
WO2020138481A1 (ja) 2020-07-02
JPWO2020138481A1 (ja) 2021-09-27
MA54619A (fr) 2021-11-03

Similar Documents

Publication Publication Date Title
CN113226314B (zh) 吡咯烷化合物的晶体
US10023577B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
US8501753B2 (en) Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one
EP3205653B1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
JP2026012851A (ja) ノボビオシン類似体とプロリンとの共結晶形態
JP2024525254A (ja) ウロデシン塩
TWI919623B (zh) 吡咯啶化合物的結晶
WO2023061372A1 (zh) 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
HK40130190A (en) Crystal of pyrrolidine compound
JP2017530107A (ja) ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶
JP2015534989A (ja) ｛ｓ−３−（４−アミノ−１−オキソ−イソインドリン−２−イル）（ピペリジン−３，４，４，５，５−ｄ５）−２，６−ジオン｝の固体形態
CN116178277A (zh) 氯比普兰甲磺酸盐晶型及其制备方法
WO2026037326A1 (zh) 吡啶酰胺类化合物的盐和晶型及其制备方法
KR20260056135A (ko) 갑상선 안질환 치료를 위한 린시티닙의 결정질염
HK40121018A (zh) 5h-吡咯并[2，3-d]嘧啶-6(7h)-酮及其盐体的结晶
CN114671826A (zh) 一种莫沙必利有机酸晶体
JP2021505602A (ja) 腎外髄質カリウムチャネル阻害剤の結晶形およびその調製方法
BRPI0904938A2 (pt) método de obtenção de um co-cristal de lamivudina, seu sal maleato, formulações farmacêuticas e seu uso

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant